|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9550 EUR | -1.14% |
|
-2.75% | -1.55% |
| 17/11 | Lavipharm 9-month net profit down to EUR 3.5 million | RE |
| 18/25/18 | Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y | RE |
| Capitalization | 16Cr 19Cr 15Cr 14Cr 27Cr 1.75TCr 28Cr 175Cr 69Cr 830.85Cr 72Cr 71Cr 3.03TCr | P/E ratio 2023 |
71.4x | P/E ratio 2024 | 14.9x |
|---|---|---|---|---|---|
| Enterprise value | 19Cr 23Cr 18Cr 17Cr 31Cr 2.05TCr 33Cr 205.31Cr 81Cr 974.72Cr 84Cr 83Cr 3.56TCr | EV / Sales 2023 |
3.1x | EV / Sales 2024 | 3.07x |
| Free-Float |
38.34% | Yield 2023 * |
-
| Yield 2024 | 2.52% |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | -1.14% | ||
| 1 week | -2.75% | ||
| Current month | -1.55% | ||
| 1 month | +2.14% | ||
| 3 months | +19.67% | ||
| 6 months | +16.46% | ||
| Current year | -1.55% |
| 1 week | 0.95 | 0.99 | |
| 1 month | 0.91 | 1 | |
| Current year | 0.95 | 1 | |
| 1 year | 0.65 | 1 | |
| 3 years | 0.37 | 1.01 | |
| 5 years | 0.35 | 2.22 | |
| 10 years | 0.16 | 2.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 01/12/2021 | |
Ligia Panaitescu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Director/Board Member | 76 | - | |
Minas G. Tanes
CHM | Chairman | 86 | 01/01/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.14% | -2.75% | +18.19% | +119.04% | 19Cr | ||
| -3.68% | -7.04% | -9.67% | +55.09% | 4.42TCr | ||
| -0.75% | +2.27% | +50.26% | - | 3.34TCr | ||
| +0.91% | -1.50% | +12.46% | +116.80% | 2.96TCr | ||
| -1.00% | -5.92% | -4.43% | +29.45% | 1.24TCr | ||
| -0.87% | -2.42% | -12.19% | +97.67% | 975.68Cr | ||
| -0.75% | -3.77% | +70.23% | +40.07% | 832.82Cr | ||
| -1.36% | +0.46% | +46.80% | +127.08% | 783.87Cr | ||
| -.--% | +0.14% | - | - | 678.76Cr | ||
| +0.58% | -0.70% | +39.38% | -21.92% | 666.8Cr | ||
| Average | -0.82% | -1.48% | +23.45% | +70.41% | 1.59TCr | |
| Weighted average by Cap. | -1.25% | -1.45% | +17.47% | +70.76% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 5.09Cr 5.98Cr 4.72Cr 4.44Cr 8.26Cr 543.84Cr 8.86Cr 54Cr 22Cr 258.6Cr 22Cr 22Cr 943.7Cr | 5.29Cr 6.21Cr 4.91Cr 4.61Cr 8.59Cr 565.37Cr 9.21Cr 57Cr 22Cr 268.84Cr 23Cr 23Cr 981.08Cr |
| Net income | 18.71L 21.95L 17.34L 16.3L 30.35L 20Cr 32.55L 2Cr 79.05L 9.5Cr 82.32L 80.63L 35Cr | 89.82L 1.05Cr 83.22L 78.27L 1.46Cr 96Cr 1.56Cr 9.61Cr 3.8Cr 46Cr 3.95Cr 3.87Cr 166.43Cr |
| Net Debt | 2.4Cr 2.82Cr 2.23Cr 2.1Cr 3.9Cr 256.74Cr 4.18Cr 26Cr 10Cr 122.08Cr 11Cr 10Cr 445.51Cr | 2.83Cr 3.32Cr 2.63Cr 2.47Cr 4.6Cr 302.57Cr 4.93Cr 30Cr 12Cr 143.87Cr 12Cr 12Cr 525.04Cr |
More financial data
* Estimated data
Employees
282
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | 0.9550 € | -1.14% | 1,17,776 |
| 19/26/19 | 0.9660 € | -0.92% | 1,71,811 |
| 16/26/16 | 0.9750 € | +1.25% | 1,11,376 |
| 15/26/15 | 0.9630 € | -1.43% | 1,54,708 |
| 14/26/14 | 0.9770 € | -0.31% | 62,329 |
Delayed Quote Athens S.E., January 20, 2026 at 08:45 pm IST
More quotes- Stock Market
- Equities
- LAVI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















